Migraine Drugs Market Analysis
Migraine Drugs Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
Migraine is a neurological disorder that causes severe pain in head and results in nausea, vomiting, and extreme sensitivity to light and sound. The common types of migraine are with aura and without aura that means classical migraines and common migraines. Women are more prone to this disease than men. Therapeutic agents such as anti-inflammatory drugs (NSAIDs), for example aspirin, ibuprofen, sumatriptan, zolmitriptan, naproxen, anti sickness medicines and many more drugs are used to cure or lower the migraine. The symptoms of migraine can begin in childhood or in adulthood and it may progress through four stages such as prodrome, aura, headache and postdrome. Whereas aura occurs before or during a migraine, it is a symptom of nervous system that usually leads to visual disturbance such as flashes of light or zigzag vision. In this visual disturbance, around 20 to 60 minutes of vision loss occurs, also the pins, needles sensation in arms can be felt. Furthermore, it may lead to difficulty in speaking and can cause for uncontrollable movements of body.
The factors that trigger migraines include hormonal changes in female body, salty food and processed food, alcohol drinks, medications such as oral contraceptive and vasodilators for example nitroglycerin can cause migraines. Latest technology such as a new, smartphone controlled wireless patch has been devised that uses electrical stimulation to reduce the pain of migraines is going to be a revolutionary for migraine patients,
Migraine drugs market taxonomy
Global Migraine Drugs Market by Drugs Type:
Global Migraine Drugs Market by Geography:
Emerging drugs expected to boost the growth of migraine drugs market in the near future
The launch of new drugs in market is expected to boost the margarine drugs market in the forecast period. For example, the Indian pharmaceutical company Cadila Healthcare Ltd. (Zydus Cadila) received the final approval on June 20, 2017, from the Food and Drug Administration (FDA) to market Eletriptan Hydrobromide tablets (20 mg and 40 mg), which is used in the treatment of migraine.
Furthermore, another Indian pharmaceutical company Novartis has filed its migraine drug erenumab with the European Medicines Agency (EMA) on June 21, 2017. Which is expected to put other pharmaceutical companies into racing to develop a new drug for the treatment of migraine.
Teva Pharmaceuticals Industries Ltd. an Israeli multinational pharmaceutical company which expected to file approval for fremanezumab (TEV-48125) drug by Food and Drug Administration (FDA) later this year (2017). This drug will be used in chronic migraine and the episodic migraine treatment, and this drug is expected to commercialize in market by the second half of 2018.
Migraine disorders are among the most common disorders of the nervous system, it has been almost seen in adult population. Furthermore, North America holds the largest share in the migraine drug market as it holds a large number of ageing population, according to the U.S. Census Bureau in 2013 the aging population was around 14.1%As per World Health Organization (WHO) in 2016, globally it has been estimated that 50% of migraine disorders was found and percentage of this disorders is found high in women due to the hormonal influences. Also, according to the National Headache Foundation (NHF), people from the U.S. spend more than US$ 4 billion annually on drugs in the treatment of migraine pain. The factors influencing for migraine drugs market include increase in awareness about migraine treatment drugs and advancement in technology in the development of migraine drugs.
According to the Migraine Research Foundation (MRF), migraine is a common neurological disease, around 38 million population including men, women and children in the U.S and 1 billion population around the globe is affected by it as of 2017. Excessive consumption of alcohol and increase in consumption of oral contraceptives significantly increases number of migraine disorder cases.
Migraine Drugs Market Key Players Includes:
The increased focus on drug development expected to support the market expansion of migraine drugs market players. There are various players across the globe running into the competition includes Endo International plc, Pfizer Inc., Aegis Therapeutics, LLC., Aeriel BioPharma, Alder BioPharmaceuticals Inc., Amgen Inc., Astellas Pharma Inc., CoLucid Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., IntelGenx Corp., Johnson & Johnson, Kowa Pharmaceuticals America, Luitpold Pharmaceuticals, Teva Pharmaceutical Industries LTD., Valeant Pharmaceuticals International, Inc., WINSTON PHARMACEUTICALS, Inc., Zogenix Inc., Abbott Laboratories, AstraZeneca plc, and GlaxoSmithKline plc.
Migraine Drugs Market Taxonomy:
Global Migraine Drugs Market by Drugs Type:
Global Migraine Drugs Market by Route of Administration:
Global Migraine Drugs Market by Distribution Channel: